BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28481779)

  • 1. Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    Martín de la Fuente L; Malander S; Hartman L; Jönsson JM; Ebbesson A; Nilbert M; Måsbäck A; Hedenfalk I
    Int J Gynecol Pathol; 2018 Mar; 37(2):101-109. PubMed ID: 28481779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
    Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
    Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
    Weberpals JI; Tu D; Squire JA; Amin MS; Islam S; Pelletier LB; O'Brien AM; Hoskins PJ; Eisenhauer EA
    Ann Oncol; 2011 Nov; 22(11):2403-2410. PubMed ID: 21368065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
    Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
    Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
    J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
    J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the 'Malova' ovarian cancer study.
    Heeran MC; Rask L; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Jarle Christensen IB; Høgdall EV
    APMIS; 2015 May; 123(5):401-9. PubMed ID: 25846370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
    Wang Y; Li M; Meng F; Lou G
    Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
    Cho HY; Kim K; Kim YB; Kim H; No JH
    Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.